Investor Presentaiton

Commercial excellence positions Guardant to lead the future of oncology testing INVESTOR 20 DAY 23 #1 ♡ Liquid biopsy CGP market share¹ Field team overall satisfaction² Share of voice1 1. Guardant360 Brand Tracker Q4 2022; 250+ team rated first in customer satisfaction by HCPs for past 7 quarters; 50% more oncology interactions compared to closest CGP company. *Growth is ordering oncologists/quarter and tests per oncologist/quarter, 2 Q2 2023 Brand Tracker 94

View entire presentation